Alderson Kory L, Sondel Paul M
Department of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
J Biomed Biotechnol. 2011;2011:379123. doi: 10.1155/2011/379123. Epub 2011 May 24.
Natural killer (NK) cells are powerful effector cells that can be directed to eliminate tumor cells through tumor-targeted monoclonal antibodies (mAbs). Some tumor-targeted mAbs have been successfully applied in the clinic and are included in the standard of care for certain malignancies. Strategies to augment the antitumor response by NK cells have led to an increased understanding of how to improve their effector responses. Next-generation reagents, such as molecularly modified mAbs and mAb-cytokine fusion proteins (immunocytokines, ICs) designed to augment NK-mediated killing, are showing promise in preclinical and some clinical settings. Continued research into the antitumor effects induced by NK cells and tumor-targeted mAbs suggests that additional intrinsic and extrinsic factors may influence the antitumor response. Therefore more research is needed that focuses on evaluating which NK cell and tumor criteria are best predictive of a clinical response and which combination immunotherapy regimens to pursue for distinct clinical settings.
自然杀伤（NK）细胞是强大的效应细胞，可通过肿瘤靶向单克隆抗体（mAb）定向清除肿瘤细胞。一些肿瘤靶向mAb已成功应用于临床，并被纳入某些恶性肿瘤的治疗标准。增强NK细胞抗肿瘤反应的策略使人们对如何改善其效应反应有了更多了解。下一代试剂，如旨在增强NK介导杀伤作用的分子修饰mAb和mAb-细胞因子融合蛋白（免疫细胞因子，IC），在临床前和一些临床环境中显示出前景。对NK细胞和肿瘤靶向mAb诱导的抗肿瘤作用的持续研究表明，其他内在和外在因素可能影响抗肿瘤反应。因此，需要更多的研究来评估哪些NK细胞和肿瘤标准最能预测临床反应，以及针对不同临床环境应采用哪些联合免疫治疗方案。
